Becton Dickinson and Co (BDX) VP Sells $5,349,714.70 in Stock
Becton Dickinson and Co (NYSE:BDX) VP Jeffrey S. Sherman sold 28,765 shares of the stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $185.98, for a total value of $5,349,714.70. Following the sale, the vice president now owns 70,821 shares of the company’s stock, valued at approximately $13,171,289.58. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Becton Dickinson and Co (NYSE:BDX) traded down 0.33% during midday trading on Friday, reaching $186.16. The company had a trading volume of 643,163 shares. The firm has a 50-day moving average of $183.68 and a 200-day moving average of $177.26. Becton Dickinson and Co has a 12 month low of $161.29 and a 12 month high of $187.69. The stock has a market cap of $39.71 billion, a P/E ratio of 30.92 and a beta of 1.00.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Tuesday, May 2nd. The medical instruments supplier reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.23 by $0.07. The business had revenue of $2.97 billion during the quarter, compared to analysts’ expectations of $2.92 billion. Becton Dickinson and had a return on equity of 25.25% and a net margin of 10.54%. The firm’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.18 earnings per share. On average, equities analysts expect that Becton Dickinson and Co will post $9.44 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 30th. Shareholders of record on Friday, June 9th will be given a dividend of $0.73 per share. The ex-dividend date is Wednesday, June 7th. This represents a $2.92 annualized dividend and a yield of 1.56%. Becton Dickinson and’s dividend payout ratio is currently 48.42%.
A number of hedge funds and other institutional investors have recently made changes to their positions in BDX. Crestwood Advisors Group LLC purchased a new position in shares of Becton Dickinson and during the first quarter valued at approximately $101,000. North Star Investment Management Corp. increased its position in shares of Becton Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after buying an additional 18 shares in the last quarter. Almanack Investment Partners LLC. purchased a new position in shares of Becton Dickinson and during the first quarter valued at approximately $105,000. Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new position in shares of Becton Dickinson and during the third quarter valued at approximately $108,000. Finally, Parkside Financial Bank & Trust increased its position in shares of Becton Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 9 shares in the last quarter. Institutional investors and hedge funds own 82.30% of the company’s stock.
BDX has been the subject of several recent analyst reports. Jefferies Group LLC restated a “buy” rating and set a $200.00 target price on shares of Becton Dickinson and in a research note on Wednesday, March 29th. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $206.00 price objective for the company in a research report on Tuesday, April 11th. Royal Bank of Canada reiterated a “hold” rating and issued a $177.00 price objective on shares of Becton Dickinson and in a research report on Thursday, April 13th. Finally, Evercore ISI upgraded Becton Dickinson and from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $186.00 to $200.00 in a research report on Monday, April 24th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $186.09.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co and related companies with MarketBeat.com's FREE daily email newsletter.